^
Association details:
| Biomarker: | IFNG overexpression |
|---|---|
| Cancer: | Esophageal Squamous Cell Carcinoma |
| Drug: | Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial
Published date:
03/13/2023
Excerpt:
In this single-arm phase 2 trial, patients with resectable (stage II/III/IV without metastasis) ESCC were enrolled and received nanoparticle albumin-bound (nab) paclitaxel for two cycles and oral S-1 for 2 weeks, combined with intravenous toripalimab...The association of the response rate with the expression level of serum proteins was analyzed...predictive efficacy of these six proteins was analyzed, and it was found that patients with high expression of IFN-γ and LAMP3 and low expression of Gal.1 had a longer OS...In this study, neoadjuvant therapy with toripalimab, nab-paclitaxel and S-1 was less toxic and showed promising antitumor activity in patients with resectable ESCC.
Secondary therapy:
albumin-bound paclitaxel + gimeracil/oteracil/tegafur
DOI:
10.1016/j.ebiom.2023.104515
